- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.04. | Kooperation mit Bristol Myers Squibb: Atrium Therapeutics sichert sich Meilensteinzahlung von 15 Mio. US-Dollar | 24 | Investing.com Deutsch | ||
| 23.04. | Atrium Therapeutics earns $15M from Bristol Myers Squibb | 5 | Investing.com | ||
| 23.04. | Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration | 220 | PR Newswire | SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics... ► Artikel lesen | |
| ATRIUM THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.04. | Atrium Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 02.03. | Novartis spaltet Atrium Therapeutics aus Avidity-Übernahme ab | 30 | transkript.de | ||
| 01.03. | Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions | 7 | MedCity News | ||
| 27.02. | Atrium Therapeutics spins out of Avidity, aiming to target rare heart diseases with RNA | 8 | BioPharma Dive | ||
| 27.02. | Atrium Therapeutics arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates | 6 | FierceBiotech | ||
| 27.02. | Atrium Therapeutics Launches with $270M | 2 | Contract Pharma | ||
| 27.02. | Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies | 973 | PR Newswire | Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform
Lead candidates ATR 1072... ► Artikel lesen | |
| 26.02. | Atrium Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.02. | Atrium Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,755 | -0,02 % | Pfizer Reports Positive Results From Phase 3 MagnetisMM-5 Study Of ELREXFIO In Multiple Myeloma | NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) on Wednesday reported positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO in adults with relapsed or refractory multiple... ► Artikel lesen | |
| GILEAD SCIENCES | 111,90 | +0,34 % | Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel | FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the... ► Artikel lesen | |
| TEVA | 29,500 | -1,34 % | Teva Pharmaceutical: Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets | Teva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines and reduced environmental impact.Through its global access to medicines programs... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 367,60 | +0,93 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| VIATRIS | 12,728 | -0,06 % | Viatris presents data on low-dose contraceptive patch at ACOG | ||
| EYEPOINT | 11,000 | -2,65 % | EyePoint, Inc.: EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 | ||
| BAUSCH HEALTH | 5,235 | +7,32 % | Bausch Health Companies Inc.: Bausch Health Announces First Quarter 2026 Results | First Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year period
GAAP Net Loss... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 64,22 | +0,75 % | Oppenheimer raises Ionis Pharmaceuticals price target on guidance | ||
| ASSEMBLY BIOSCIENCES | 22,650 | -0,88 % | Assembly Biosciences-Aktie: "Weitere signifikante Meilensteine" erwartet | Für Aktionäre von Assembly Biosciences war 2025 ein Jahr, das den strategischen Kurs des Unternehmens eindrucksvoll bestätigte. Mehrere klinische Programme lieferten positive Daten, teilweise sogar... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 72,54 | +0,11 % | Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares | SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 260,70 | -1,14 % | Alnylam Reports Q1 Net Profit As Product Revenue Surges; Stock Up 8% In Pre-Market | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc.(ALNY), an RNAi therapeutics company, on Thursday reported a net income for the first quarter of fiscal 2026, supported by a surge in revenue... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,268 | +2,26 % | FILANA THERAPEUTICS, INC. - 8-K, Current Report | ||
| AMARIN | 11,700 | 0,00 % | Amarin Corporation plc: Amarin Reports 2026 First Quarter Financial Results | Total Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,245 | -2,26 % | Lifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with Oramed | HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 177,00 | -0,08 % | XFRA 19X: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAXSOME THERAPEUT.... ► Artikel lesen |
Das Unternehmen ATRIUM THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 13,400 Euro und damit +4,93 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATRIUM THERAPEUTICS INC finden Sie auf Wallstreet Online.